Skip to content
Calculator
Compare

ARA-290 vs BPC-157

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

Two people bandaging an injured hand
Photo by RDNE Stock project on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • ARA-290 has small placebo-controlled human trials, mostly in nerve pain from sarcoidosis and diabetes. BPC-157 has decades of rodent data and three small, poor-quality human studies with 30 people in all 8.
  • They were tested for different things: ARA-290 for small-fibre neuropathy, BPC-157 in animals for gut, tendon and muscle healing.
  • Neither is FDA-approved. Both are prohibited in sport 1.

Side by side

ARA-290 Medium and BPC-157 Low are often sold side by side as repair peptides. Their evidence comes from different places: ARA-290 from small human trials, BPC-157 mainly from animals 1. The table is read from our encyclopedia entries.

FieldARA-290BPC-157
Encyclopedia entryARA-290 Full entryBPC-157 Full entry
Molecule classPeptidePeptide
CategoryHealing & RecoveryHealing & Recovery
FDA statusIn Clinical TrialsResearch Chemical
Approved elsewhereNone recordedNone recorded
Evidence gradeMediumLow
Half-lifeShort; no human value in the published abstractsShort systemic half-life (minutes) but prolonged tissue effect
FormulaC51H84N16O21C62H98N16O22
Molecular weight1,257.3 g/mol1,419.5 g/mol
WADA 2026Prohibited at all times (S2.1.5)Prohibited at all times (S0)
WADA 2027Prohibited at all times (S2.1.5)Prohibited at all times (S0)
In one lineAn 11-amino-acid EPO-derived peptide studied for neuropathic pain and tissue protection, without the red-cell-stimulating effects of full erythropoietin.A synthetic pentadecapeptide from gastric protein, widely studied in animal models for tendon, ligament, and gastrointestinal healing.
MechanismAgonist at the innate repair receptor, the heteromeric complex of the erythropoietin receptor and the β-common receptor (CD131), designed from the aqueous face of EPO's helix B. In animal studies it reduced inflammatory signalling (CD131- and JAK2-dependent inhibition of NF-κB p65 in macrophages), neuronal apoptosis after stroke and renal injury after ischaemia, and inhibited the TRPV1 pain channel, without stimulating erythropoiesis, which runs through EPO-receptor homodimers.BPC-157 promotes angiogenesis via upregulation of VEGFR2 expression and activation of the Egr-1/NAB2 pathway, modulates nitric oxide signaling, and interacts with the dopaminergic and serotonergic systems in animal models. Effects are observed on tendon, ligament, muscle, bone, gastrointestinal tissue, and the blood-brain barrier. Despite extensive preclinical literature, no peer-reviewed human efficacy trials have been published as of 2026.
Sources in the entry1524
Study cards1221
Dosage pageNoneDosage page

ARA-290: small human trials in nerve pain

ARA-290, also called cibinetide, is an 11-amino-acid peptide modelled on a part of erythropoietin (EPO) 1, designed to protect tissue without stimulating red-cell production 2. It is investigational and not approved anywhere 1. In 22 patients with sarcoidosis and small-fibre neuropathy, four weeks of intravenous ARA-290 improved a neuropathy screening score by 11.5 points against 2.9 on placebo (randomised trial) 3. In a larger dose-ranging trial in the same condition, 4 mg a day for 28 days increased corneal nerve fibre area against placebo, while other doses did not reach significance (randomised trial) 4. In type 2 diabetes with neuropathy, 4 mg daily for 28 days improved HbA1c, lipids and neuropathic symptoms (randomised phase 2 trial) 2.

Not every test succeeded. In diabetic macular oedema, 12 weeks of daily self-injection did not improve visual acuity or retinal thickness in a small study (human study) 5.

BPC-157: animal healing data, little human data

BPC-157 is a synthetic 15-amino-acid peptide 1 described by its originators as a stable gastric pentadecapeptide. Its reputation rests on decades of rodent studies, many from the Zagreb group that first described it, showing faster healing of gut, tendon, ligament, muscle and bone injuries (animal evidence) 6. A 2025 systematic review found preclinical support for musculoskeletal healing, noted that clinicians and athletes increasingly use it, and found no clinical safety data (systematic review) 7. A 2026 systematic review found three human studies, 30 people in all, each uncontrolled or poor in quality, and advised against clinical use outside regulated trials 8: two adults given intravenous infusions without measured side effects 9, a chart review of knee injections in 16 patients reached by phone 10, and a bladder-injection pilot in interstitial cystitis 8. That review searched to June 1, 2026. FDA's May 2026 briefing counts five clinical studies, about 108 people, adding two older enema studies, one in healthy volunteers and a randomised, placebo-controlled study in ulcerative colitis reported only as a 2005 meeting abstract, whose data FDA judged inadequate 11. A September 2026 report described three dental patients given BPC-157 together with ARA-290, TB-500 and other drugs by injection, without a control group, so no effect can be credited to either peptide 12.

Different targets, different questions

The two are not really competitors. ARA-290's trials were in neuropathic pain and small-nerve damage, and measured nerve fibres and pain scores 3 4. BPC-157 is used for muscle and tendon tears 9 on the strength of animal studies 6. Someone choosing between them for a torn tendon would find no human tendon data for either; someone with diagnosed small-fibre neuropathy would find that only ARA-290 has been tested, in small trials, and that it is investigational 1.

Their mechanisms differ too. ARA-290 acts through the innate repair receptor, a complex of the EPO receptor with the beta-common receptor, and in mice with colitis it reduced inflammation through that receptor's CD131 subunit (animal evidence) 13.

How the differences add up (as of October 27, 2026)

On human evidence ARA-290 is ahead: several small randomised trials, with mixed but sometimes positive results in nerve pain. BPC-157 has more animal data and a handful of small human studies, its one randomised study known only from a meeting abstract 8 11. Neither is FDA-approved. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may use in compounding, as reported (FDA has posted no tallies) 14; FDA had not acted on that as of October 27, 2026 15. In sport, ARA-290 is prohibited under S2.1.5 as an EPO-receptor agonist, and BPC-157 under S0 1. Our KPV vs BPC-157 and BPC-157 vs GHK-Cu comparisons cover other pairings. Doses on this page are those in our entries' sources, not recommendations.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 16. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

Frequently asked questions

What is the difference between ARA-290 and BPC-157?

ARA-290 is an EPO-derived peptide tested in small human trials for nerve pain; BPC-157 is a synthetic gastric pentadecapeptide with extensive animal healing data and a handful of small human studies.

Which has better human evidence?

ARA-290, with several small placebo-controlled trials in small-fibre neuropathy. BPC-157's human record is small: three poor-quality studies with 30 people in a 2026 systematic review, or five studies with about 108 people in FDA's May 2026 briefing, whose one randomised study exists only as a 2005 meeting abstract.

Are ARA-290 and BPC-157 legal?

Neither is FDA-approved. Both are prohibited in sport: ARA-290 under S2.1.5 and BPC-157 under S0.

Sources

  1. Grey Peptides dataset records for ARA-290 (cibinetide) and BPC-157 (FDA status, sequences, WADA 2026 and 2027 status, studied doses as sourced on each entry); read October 27, 2026.
  2. Brines, M., et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med, 20(1), 658-66. PMID: 25387363
  3. Heij, L., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med, 18(1), 1430-6. PMID: 23168581
  4. Culver, D. A., et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci, 58(6), BIO52-BIO60. PMID: 28475703
  5. Lois, N., et al. (2020). A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med, 9(7). PMID: 32674280
  6. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24(18), 1972-1989. PMID: 29998800
  7. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
  8. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452
  9. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  10. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  11. U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee, dated May 11, 2026: five clinical studies found in PubMed and Embase (rectal enemas in 24 healthy subjects; a multicentre, randomised, double-blind, placebo-controlled enema study in ulcerative colitis, 53 randomised, reported only as a 2005 meeting abstract, its data judged inadequate to support efficacy or safety; intra-articular injections in 17 people with knee pain; an intravesical injection in 12 with interstitial cystitis; intravenous infusions in 2 healthy subjects), 108 people by its own counts. Read October 28, 2026. FDA
  12. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
  13. Nairz, M., et al. (2017). Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep, 7(1), 13012. PMID: 29026145
  14. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Cited without a link.
  15. U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee page (no minutes or vote tallies posted) and 503A category list (updated May 14, 2026). Re-read October 27, 2026.
  16. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead